AKT1 and non-small cell lung carcinoma: Decreased DUSP1 expression results in continuous RAS/MAPK activation and causes gefitinib resistance in NSCLC.395 Moreover, lncRNA-PCAT-1 may increase the phosphorylation of AKT and GSK3, resulting in sustained activation of PI3K/AKT and gefitinib resistance.396 LncRNA-HIF1A-AS2 induces IL-6 expression by binding to miR-146b-4p and activating the IL-6/STAT pathway.